Original Article

You have full text access to this OnlineOpen article

Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial

  1. Robert J. Fontana M.D.1,
  2. Jonathan Israel2,
  3. Paula LeClair3,
  4. Barbara F. Banner3,
  5. Kristina Tortorelli3,
  6. Norman Grace4,
  7. Robert A. Levine5,*,
  8. Gale Fiarman6,
  9. Michael Thiim6,†,
  10. Anthony S. Tavill7,
  11. Herbert L. Bonkovsky3

Article first published online: 30 DEC 2003

DOI: 10.1002/hep.510310325

Issue

Hepatology

Hepatology

Volume 31, Issue 3, pages 730–736, March 2000

Additional Information

How to Cite

Fontana, R. J., Israel, J., LeClair, P., Banner, B. F., Tortorelli, K., Grace, N., Levine, R. A., Fiarman, G., Thiim, M., Tavill, A. S. and Bonkovsky, H. L. (2000), Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial. Hepatology, 31: 730–736. doi: 10.1002/hep.510310325

Author Information

  1. 1

    University of Michigan Medical School, Ann Arbor, MI

  2. 2

    Hartford Hospital and University of Connecticut School of Medicine, Hartford, CT

  3. 3

    University of Massachusetts Medical School and U. Mass Memorial Health Care, Worcester, MA

  4. 4

    Faulkner Hospital and Tufts University School of Medicine, Boston, MA

  5. 5

    State University of New York Health Sciences Center at Syracuse, NY

  6. 6

    Lahey Clinic, Burlington, MA

  7. 7

    Mt. Sinai Medical Center and Case Western Reserve University, Cleveland, OH

  1. †

    GI unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Dr. Fiarman's current address is Harvard Community Health Plan, Boston, MA

*Division of Gastroenterology, University of Michigan Medical School, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109. fax: (734) 936-7392

Publication History

  1. Issue published online: 30 DEC 2003
  2. Article first published online: 30 DEC 2003
  3. Manuscript Accepted: 9 DEC 1999
  4. Manuscript Received: 15 SEP 1999

Funded by

  • NIH (to H.L.B.). Grant Number: DK38825
  • Schering-Plough Inc., Kenilworth, NJ

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (126K)

References

  • 1
    Seeff LB. Natural history of hepatitis C. Hepatology 1997; 26(Suppl):21S–28S.MEDLINE
    Direct Link:
  • 2
    Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26(Suppl):112S–122S.MEDLINE
    Direct Link:
  • 3
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485–1492.MEDLINE
  • 4
    Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339:1493–1499.MEDLINE
  • 5
    Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26(Suppl):122S–127S.MEDLINE
    Direct Link:
  • 6
    Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon therapy is influenced by the iron content of the liver. J Hepatol 1994; 20:410–415.MEDLINE
  • 7
    Kaji K, Nakanuma Y, Sasaki M, Unoura M, Kobayashi K, Nonomura A. Hemosiderin deposition in portal endothelial cells: a novel hepatic hemosiderosis frequent in chronic viral hepatitis B and C. Hum Pathol 1995; 26:1080–1085.MEDLINE
  • 8
    Olynyk J, Reddy R, DiBisceglie AM, Jeffers LJ, Parker Radick J, Schiff ER, Bacon BR. Hepatic iron concentration as a predictor of response to interferon alpha therapy in chronic hepatitis C. Gastroenterology 1995; 108:1104–1109.MEDLINE
  • 9
    Fargion S, Fracanzani L, Sampietro M, Molteni V, Boldorini R, Mattioli, Cesana B, et al. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol 1997; 9:497–503.MEDLINE
  • 10
    Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997; 25:759–768.MEDLINE
    Direct Link:
  • 11
    Bacon BR, Rebholz AE, Fried M, DiBisceglie AM. Beneficial effect of iron reduction therapy in patients with chronic hepatitis C who failed to respond to interferon [Abstract]. Hepatology 1993; 373:150A.
  • 12
    Hayashi H, Takikawa T, Nishimura N, Yano M, Isomuar T, Sakomoto. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994; 89:986–988.MEDLINE
  • 13
    Rubin RB, Barton A, Banner BF, Bonkovsky HL. Iron and chronic viral hepatitis: emerging evidence for an important interaction. Dig Dis 1995; 13:223–238.MEDLINE
  • 14
    Sampietro PA, D'Alba M, Roffi L, Fargion S, Parma S, Nicoli C, Corbetta N, et al. Iron stores, response to interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 1996; 16:248–254.MEDLINE
  • 15
    Van Thiel DH, Friedlander L, Molloy P, Kania RJ, Fagiuoli S, Wright HI, Gasbarriini A, et al. Retreatment of hepatitis C interferon non-responders with larger doses of IFN with and without phlebotomy. Hepatogastroenterology 1996; 43:1557–1561.MEDLINE
  • 16
    Tsai NC-S, Zuckerman E, Han S-H, Goad K, Redeker AG, Fong TL. The effect of iron depletion on long-term response to interferon in patients with chronic hepatitis C who previously did not respond to interferon therapy. Am J Gastroenterol 1997; 92:1831–1834.MEDLINE
  • 17
    Idilman R, Maria N de, Colantoni A, Dokmeci A, Van Thiel DH. Interferon treatment of cirrhotic patients with chronic hepatitis C. J Viral Hepat 1997; 4:81–91.MEDLINE
  • 18
    Banner BF, Barton AL, Cable EE, Smith L, Bonkovsky HL. A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C. Mod Pathol 1995; 8:232–238.MEDLINE
  • 19
    Barton AL, Banner BF, Cable EE, Bonkovsky HL. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am J Clin Pathol 1995; 103:419–424.MEDLINE
  • 20
    Ikura Y, Morimot H, Johmura H, Fukui M, Sakurai M. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. Am J Gastroenterol 1996; 91:1367–1373.MEDLINE
  • 21
    Pockros PJ, Bain VG, Hunter EB, Conrad A, Balart A, Hollinger FB, Albert D. A comparison of reverse transcription–polymerase chain reaction and branched DNA assays for hepatitis C virus RNA in patients receiving interferon treatment. the Consensus Interferon Study Group. J Viral Hepat 1999; 6:145–150.MEDLINE
    Direct Link:
  • 22
    Stuvyer L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuveryswyn H, Maertens G. Typing of hepatitis C virus isolates and characterization of new genotypes. J Gen Virol 1993; 74:1093–1102.MEDLINE
  • 23
    Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, Obando J, DiBisceglie A, Tattrie C, Tortorelli K, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998; 27:1661–1669.MEDLINE
    Direct Link:
  • 24
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan, Wooman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431–435.MEDLINE
    Direct Link:
  • 25
    MacSween RNM, Anthony PP, Scheuer PJ. Pathology of the Liver. Edinburgh: Churchill Livingstone. 1987;185.
  • 26
    Lau JYN, Davis GL, Kniffen J, Qian K, Urdea MS, Chan CS, Mizokami M, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341:1501–1504.MEDLINE
  • 27
    Tong MJ, Reddy R, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, Hollinger FB, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Hepatology 1997; 26:747–754.MEDLINE
    Direct Link:
  • 28
    Heathcote EJL, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, Albert DG, et al. Retreatment of chronic hepatitis C with consensus interferon. Hepatology 1998; 27:1136–1143.MEDLINE
    Direct Link:
  • 29
    Reddy RK, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, et al. for the Consensus Interferon Study Group. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999; 30:787–793.MEDLINE
    Direct Link:
  • 30
    Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, et al. A novel MHC class I–like gene is mutated in patients with hereditary hemochromatosis. Nat Genet 1996; 13:399–408.MEDLINE
  • 31
    Beutler E, Gelbart T, West C, Lee P, Adams M, Blackstone R, Pockros P, et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 1996; 22:187–194.MEDLINE
  • 32
    National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C. Hepatology 1997; 26(Suppl):2S–10S.MEDLINE
  • 33
    DiBisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992; 102:2108–2113.MEDLINE
  • 34
    Arber N, Konikoff FM, Moshkowitz M, Baratz M, Hallak A, Santo M, Halpern Z, et al. Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases. Dig Dis Sci 1994; 39:2656–2659.MEDLINE
  • 35
    Barbaro G, DiLorenzo G, Ribersani M, Soldini M, Giancespro G, Bellomo G, Belloni G, et al. Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype. J Hepatol 1999; 30:774–782.MEDLINE
  • 36
    Farinati F, Cardin R, DeMaria N, Libera GD, Marafin C, Lecis E, Burra P, et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995; 22:449–456.MEDLINE
  • 37
    Hayashi H, Wakusaw S, Takidaw T, Ikeda R, Yano M, Yoshioka K. Long term effect of iron removal on chronic hepatitis C [Abstract]. Gastroenterology 1997; 26:A345.
  • 38
    Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon therapy. Science 1998; 282:103–107.MEDLINE
  • 39
    Fong TL, Han SH, Tsai NCS, Morgan TR, Mizokami M, Qian DJ, Phan C, et al. A pilot randomized, controlled trial of the effect of iron depletion on long term response to alpha-interferon in patients with chronic hepatitis C. J Hepatol 1998; 28:369–374.MEDLINE
  • 40
    Fargion S, Ballare M, Belloni G, Bissoli F, Borzio M, Ceriani R, Fiorelli G, et al. Iron depletion and interferon therapy: a multicenter randomized controlled trial in untreated non-cirrhotic patients with chronic hepatitis C [Abstract]. Hepatology 1999; 30:371A.
  • 41
    Bonkovsky HL. Therapy of hepatitis C: other options. Hepatology 1997; 26(Suppl):143S–151S.MEDLINE
    Direct Link:
  • 42
    Hezode C, Cazeneuve C, Coue O, Pawlotsky JM, Zafrani ES, Amselem S, Dhumeaux D. Hemochromatosis Cys282Tyr mutation and liver iron overload in patients with chronic active hepatitis C. Hepatology 1998; 27:306.MEDLINE
    Direct Link:
  • 43
    Aldersley MA, Howdle PD, Wyatt JI, Robinson PA, Markhem AF. Haemochromatosis gene mutation in liver disease patients. Lancet 1997; 349:1025–1026.MEDLINE
Get PDF (126K)